GB0423196D0 - Method - Google Patents

Method

Info

Publication number
GB0423196D0
GB0423196D0 GBGB0423196.5A GB0423196A GB0423196D0 GB 0423196 D0 GB0423196 D0 GB 0423196D0 GB 0423196 A GB0423196 A GB 0423196A GB 0423196 D0 GB0423196 D0 GB 0423196D0
Authority
GB
United Kingdom
Prior art keywords
sample
haptoglobin
formulated
isolation
subjected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0423196.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Blood Authority
Original Assignee
National Blood Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Blood Authority filed Critical National Blood Authority
Priority to GBGB0423196.5A priority Critical patent/GB0423196D0/en
Publication of GB0423196D0 publication Critical patent/GB0423196D0/en
Priority to CA2584407A priority patent/CA2584407C/en
Priority to PL05794729T priority patent/PL1802654T3/pl
Priority to BRPI0516933A priority patent/BRPI0516933B8/pt
Priority to JP2007537377A priority patent/JP4950053B2/ja
Priority to PCT/GB2005/004037 priority patent/WO2006043062A1/en
Priority to AT05794729T priority patent/ATE539085T1/de
Priority to US11/577,478 priority patent/US9145448B2/en
Priority to EP05794729A priority patent/EP1802654B1/en
Priority to MX2007004244A priority patent/MX2007004244A/es
Priority to AU2005297061A priority patent/AU2005297061B2/en
Priority to ES05794729T priority patent/ES2379157T3/es
Priority to IL182340A priority patent/IL182340A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB0423196.5A 2004-10-19 2004-10-19 Method Ceased GB0423196D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB0423196.5A GB0423196D0 (en) 2004-10-19 2004-10-19 Method
ES05794729T ES2379157T3 (es) 2004-10-19 2005-10-19 Procedimiento para el aislamiento de haptoglobina.
AT05794729T ATE539085T1 (de) 2004-10-19 2005-10-19 Verfahren zur isolierung von haptoglobin
PL05794729T PL1802654T3 (pl) 2004-10-19 2005-10-19 Sposób izolowania haptoglobiny
BRPI0516933A BRPI0516933B8 (pt) 2004-10-19 2005-10-19 métodos para o isolamento da haptoglobina humana, das isoformas de hp humana individuais, e da albumina e da haptoglobina humana
JP2007537377A JP4950053B2 (ja) 2004-10-19 2005-10-19 ハプトグロビンの単離方法
PCT/GB2005/004037 WO2006043062A1 (en) 2004-10-19 2005-10-19 Method for the isolation of haptoglobin
CA2584407A CA2584407C (en) 2004-10-19 2005-10-19 Method for the isolation of haptoglobin
US11/577,478 US9145448B2 (en) 2004-10-19 2005-10-19 Method for the isolation of haptoglobin
EP05794729A EP1802654B1 (en) 2004-10-19 2005-10-19 Method for the isolation of haptoglobin
MX2007004244A MX2007004244A (es) 2004-10-19 2005-10-19 Metodo para el aislamiento de haptoglobina.
AU2005297061A AU2005297061B2 (en) 2004-10-19 2005-10-19 Method for the isolation of haptoglobin
IL182340A IL182340A (en) 2004-10-19 2007-03-29 A method of isolating hepatoglobin from the V segment of human COHN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0423196.5A GB0423196D0 (en) 2004-10-19 2004-10-19 Method

Publications (1)

Publication Number Publication Date
GB0423196D0 true GB0423196D0 (en) 2004-11-24

Family

ID=33484812

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0423196.5A Ceased GB0423196D0 (en) 2004-10-19 2004-10-19 Method

Country Status (13)

Country Link
US (1) US9145448B2 (enExample)
EP (1) EP1802654B1 (enExample)
JP (1) JP4950053B2 (enExample)
AT (1) ATE539085T1 (enExample)
AU (1) AU2005297061B2 (enExample)
BR (1) BRPI0516933B8 (enExample)
CA (1) CA2584407C (enExample)
ES (1) ES2379157T3 (enExample)
GB (1) GB0423196D0 (enExample)
IL (1) IL182340A (enExample)
MX (1) MX2007004244A (enExample)
PL (1) PL1802654T3 (enExample)
WO (1) WO2006043062A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0423196D0 (en) 2004-10-19 2004-11-24 Nat Blood Authority Method
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
HK1212995A1 (zh) * 2012-10-03 2016-06-24 Csl Behring Ag 一种纯化蛋白质的方法
EP3917943A4 (en) * 2019-02-01 2022-12-07 Ohio State Innovation Foundation PROTEINS PURIFICATION PROCEDURES
US20220218834A1 (en) * 2019-05-20 2022-07-14 Ohio State Innovation Foundation Apohemoglobin-haptoglobin complexes and methods of using thereof
US20240034749A1 (en) * 2021-02-04 2024-02-01 Green Cross Corporation Method for purification of hemopexin and haptoglobin
CN115531921B (zh) * 2022-08-26 2024-07-16 大连依利特分析仪器有限公司 一种制备型液相色谱馏分收集装置及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061735A (en) * 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
GB1426039A (en) 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
US4137307A (en) * 1973-11-15 1979-01-30 The Green Cross Corporation Process for preparing haptoglobin aqueous solution using strong anion exchanger
JPS5337406B2 (enExample) * 1973-11-15 1978-10-09
JPS52128205A (en) * 1976-04-16 1977-10-27 Green Cross Corp:The Prophylactic and therapeutic drugs for cerebro-vascular contraction
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5094960A (en) * 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
JP3554796B2 (ja) * 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 アルブミン製剤及びその製造方法
JP3825061B2 (ja) * 1994-09-28 2006-09-20 三菱ウェルファーマ株式会社 ハプトグロビンの製造方法
DE19960500A1 (de) * 1999-12-15 2001-07-12 Giesing Michael Antikörper und Verfahren zu ihrer Herstellung, deren Verwendung sowie Immunisierungscocktails, Immunoassay-Sets und Peptide
PT1328297E (pt) * 2000-10-16 2010-01-04 Cytoguide Aps Função de um receptor de haptoglobina-hemoglobina e suas utilizações
US20030113830A1 (en) 2001-07-11 2003-06-19 Rappaport Family Institute For Research In The Medical Sciences Novel antioxidant, nucleic acid constructs encoding same, pharmaceutical compositions containing same and use of same for reducing oxidative-stress
JP2004244348A (ja) * 2003-02-13 2004-09-02 Nihon Pharmaceutical Co Ltd パプトグロビンの精製法
GB0423196D0 (en) 2004-10-19 2004-11-24 Nat Blood Authority Method
WO2006107708A1 (en) 2005-04-04 2006-10-12 Alexion Pharmaceuticals, Inc. Treatment of disease caused by excess free hemoglobin

Also Published As

Publication number Publication date
BRPI0516933B8 (pt) 2021-05-25
JP4950053B2 (ja) 2012-06-13
BRPI0516933A (pt) 2008-09-23
ES2379157T3 (es) 2012-04-23
IL182340A0 (en) 2007-07-24
EP1802654B1 (en) 2011-12-28
AU2005297061A1 (en) 2006-04-27
EP1802654A1 (en) 2007-07-04
MX2007004244A (es) 2007-09-07
JP2008517046A (ja) 2008-05-22
CA2584407C (en) 2015-02-03
AU2005297061B2 (en) 2011-09-01
US20090281282A1 (en) 2009-11-12
IL182340A (en) 2012-06-28
BRPI0516933B1 (pt) 2021-02-09
CA2584407A1 (en) 2006-04-27
WO2006043062A1 (en) 2006-04-27
ATE539085T1 (de) 2012-01-15
US9145448B2 (en) 2015-09-29
PL1802654T3 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
IL185731A0 (en) Purification of montelukast
IL182340A0 (en) Method for the isolation of haptoglobin
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
MY151036A (en) Synthesis of (r)-n-methylnaltrexone
TW200720269A (en) Apoptosis promoters
TW200716646A (en) (S)-N-methylnaltrexone
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
TW200740844A (en) Novel MAdCAM antibodies
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
TW200517381A (en) Bicyclic heteroaryl derivatives
MY142777A (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
NO20063196L (no) Nye fusjonerte pyrrolokarbazoler
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
IL165988A0 (en) Process for the preparation of fibrinogen
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
WO2004106322A3 (en) Polymorphs of aripiprazole
GB0216002D0 (en) Process and composition
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2004017949A3 (de) Prophylaxe und therapie von infektionserkrankungen mit amitryptilin oder imipramin oder desipramin oder fgf oder einem anticeramid antikörper oder cyclodextrin oder nystatin oder filipin
WO2004034985A3 (en) Chemical compounds
WO2006132739A3 (en) Novel chemical compounds
ATE424823T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)